tirzepatide vs semaglutide vs retatrutide Retatrutide vs Tirzepatide vs Semaglutide:

(average results) Wegovy (semaglutide) GLP-1 only In the STEP-1 study (68 weeks), average weight change was about: 14.9% with Wegovy 2.4% with placebo (dummy injection) What that looks like: If you start at 100 kg , 14.9% is about 15 kg lost on average

"In terms of getting patients close to a healthy weight or a BMI of 25 nothing has been shown to have the same success as bariatric surgery." Bariatric surgery also offers these health benefits: Decreased rates of uterine and esophageal cancers Faster metabolism Improved type 2 diabetes Less medication use Lower blood pressure Reduced heart failure and heart disease Dr

Tirzepatide: From Phase 3 to Pharmacy in 2.5 Years Eli Lilly started the SURMOUNT trial program for tirzepatide in late 2020

Physiol Rev 2007, 87: 14091439

The Circana study found that households with members taking the weight loss drugs typically spend more on CPG [consumer packaged goods] food, beverages, and foodservice before they initiate use of a GLP-1 than non-user households, a trend that continues even in the first year of drug use. It also found that GLP-1 weight loss users: Reduced relative household spending on spicy foods, fatty proteins, and beverages with added sugar, and increased spending on vegetables, eggs, and nuts Spent more on gum, mints, and non-chocolate candy to provide relief from the drugs side effects including bad breath and dry mouth Increased spending on drinkware and water filtration versus non-users, which could be driven by hydration recommendations Spent more on gastrointestinal products for relief from side effects of the medication Spent less on sleep remedies, analgesics, home health care, and foot care products Spent less on frozen foods and more in the produce and deli departments Spent more on foods & beverages at drug stores, perhaps because they are going there regularly to pick up meds Further reading: How are GLP-1 drugs impacting spending on food and dietary supplements

In controlled experimental environments, Retatrutide acts as a multi-receptor agonist, engaging the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors